Comparison 6. Reboxetine + betahistine versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Weight: clinically important change in weight > 5%	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.2 Weight: clinically important change in weight > 7%	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3 Weight: average endpoint/change in body weight	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.4 Weight: average endpoint/change in body mass index	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.5 Leaving the study early: for any reason	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.6 Mental state	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.6.1 Average score: SAPS (higher = worse)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.6.2 Average score: SANS (higher = worse)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.6.3 Average score: HAM‐D (higher = worse)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.6.4 Average score: CGI (higher = worse)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.7 Adverse events	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6.7.1 Neurological: BAS	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6.7.2 Neurological: SAS	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected